Next Earnings date is expected on
08/12/2022
Alaunos Therapeutics (TCRT) has an average rating of outperform and price targets ranging from $1.50 to $7.50, according to analysts polled by Capital IQ....
US stock futures are mixed during Friday's premarket session ahead of monthly inflation figures, with the Consumer Price Index for May expected to rise...
Rise Education Cayman (REDU) gained more than 240% after a change its American depositary shares ratio to 10 shares per ADS from 2 shares became effective...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
| Address | 8030 El Rio Street Houston, Texas 77054 |
| Phone | +1.346.355.4099 |
| Number of Employees | 48 |
| Recent SEC Filing | 08/04/2022 8-K |
| Chief Executive Officer & Director | Kevin S. Boyle |
| Executive Vice President-Operations | Eleanor M. de Groot |
| Chief Financial Officer | Timothy M. Cunningham |
| Vice President-Research & Development | Drew Deniger |
| Price Open | $1.68 |
| Previous Close | $1.70 |
| 52 Week Range | $0.41 - 2.43 |
| Market Capitalization | $360.6 M |
| Shares Outstanding | 216.0 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/12/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.30 |
| Beta vs. S&P 500 | N/A |
| Revenue | $146.0 K |
| Net Profit Margin | -16,830.40% |
| Return on Equity | -101.43% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
